Characteristics | SIROCCO (high-dosage ICS) | CALIMA (medium- to high-dosage ICS) | Study 3082 (medium- to high-dosage ICS) | Study 3083 (medium- to high-dosage ICS) | Study 3082 and Study 3083 (pooled) (medium- to high-dosage ICS) | |||||
Benralizumab Q8W | Placebo | Benralizumab Q8W | Placebo | Reslizumab 3 mg·kg−1 | Placebo | Reslizumab 3 mg·kg−1 | Placebo | Reslizumab 3 mg·kg−1 | Placebo | |
Patients n | 398 | 407 | 441 | 440 | 245 | 244 | 232 | 232 | 477 | 476 |
Ag mean±sd years | 47.6±14.5 | 48.7±14.9 | 49.0±14.3 | 48.8±15.1 | 46.6±13.8¶ | 46.7±14.8¶ | 46.4±13.8¶ | 47.5±13.6¶ | - | - |
Male sex % | 36.7 | 33.9 | 38.1 | 40.0 | 42.0 | 34.0 | 38.0 | 35.0 | 40.04 | 34.45 |
BMI mean±sd kg·m−2 | 28.21±6.18 | 28.93±7.07 | 29.0±6.5 | 29.25±6.54 | 27.7±6.3 | 28±6.2 | 27±5.1 | 27±5.3 | - | - |
FEV1 % pred mean | 56.1+ | 56.6+ | 57.9 | 58.0 | 63.6 | 65.0 | 70.4 | 68.0 | - | - |
Reversibility % mean | 27.2 | 25.5 | 24.6 | 27.3 | 26.1 | 26.3 | 28.1 | 28.7 | - | - |
ACQ score mean# | 2.8 | 2.87 | 2.82 | 2.73 | 2.66 | 2.76 | 2.57 | 2.61 | - | - |
Never smokers % | 82.2 | 80.6 | 78.9 | 79.3 | - | - | - | - | - | - |
OCS use % | 17.8 | 16.2 | 10.0 | 8.9 | 19.0 | 19.0 | 12.0 | 12.0 | - | - |
EOS count cells·µL−1 mean | 469.8 | 456.5 | 465.1 | 487.5 | 696.0 | 624.0 | 610.0 | 688.0 | - | - |
Exacerbations in previous year | ||||||||||
Mean | 2.8 | 3 | 2.7 | 2.8 | 1.9 | 2.1 | 1.9 | 2.0 | - | - |
1 exacerbation % | 0.0 | 0.0 | 0.2§ | 0.0 | - | - | - | - | 58.07 | 59.24 |
2 exacerbations % | 63.3 | 60.0 | 65.1 | 65.5 | - | - | - | - | 18.03 | 22.48 |
≥3 exacerbations % | 19.8 | 18.7 | 21.1 | 21.1 | - | - | - | - | 9.22 | 7.56 |
≥4 exacerbations % | 16.9 | 21.3 | 13.6 | 13.4 | - | - | - | - | 14.05 | 10.08 |
Omalizumab use % | 7.0 | 7.6 | 2.7 | 3.8 | - | - | - | - | - | - |
Nasal polyps % | 19.0+ | 19.0+ | 16.8 | 18.1 | - | - | - | - | - | - |
Data in bold indicate differences across benralizumab and reslizumab studies. For cells with no data listed, none were available. ICS: inhaled corticosteroid; Q8W: every 8 weeks (first three doses every 4 weeks); BMI: body mass index; FEV1: forced expiratory volume in 1 s; ACQ: Asthma Control Questionnaire; OCS: oral corticosteroid; EOS: eosinophil. #: ACQ-5 in benralizumab trials and ACQ-7 in reslizumab trials; ¶: extracted from reslizumab National Institute for Health and Care Excellence single technology appraisal, all other data for reslizumab trials are extracted from publications; +: data extracted from publications rather than clinical study reports; §: one patient in CALIMA had one exacerbation in the past year.